Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 29, 2025

Brilliant Violet 650[™] anti-human TNF-?

RRID:AB_2562741 Type: Antibody

Proper Citation

(BioLegend Cat# 502938, RRID:AB_2562741)

Antibody Information

URL: http://antibodyregistry.org/AB_2562741

Proper Citation: (BioLegend Cat# 502938, RRID:AB_2562741)

Target Antigen: TNF-alpha

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: ICFC, FC

Antibody Name: Brilliant Violet 650[™] anti-human TNF-?

Description: This monoclonal targets TNF-alpha

Target Organism: human

Clone ID: Clone MAb11

Antibody ID: AB_2562741

Vendor: BioLegend

Catalog Number: 502938

Alternative Catalog Numbers: 502937

Record Creation Time: 20231110T035220+0000

Record Last Update: 20240724T234916+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 650[™] anti-human TNF-?.

No alerts have been found for Brilliant Violet 650[™] anti-human TNF-?.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Zhao XJ, et al. (2024) Humoral and cellular immune responses following Omicron BA.2.2 breakthrough infection and Omicron BA.5 reinfection. iScience, 27(7), 110283.

Zhao XJ, et al. (2024) Protocol to evaluate virus-specific CD4+ and CD8+ T cell responses by spectral flow cytometry. STAR protocols, 5(4), 103497.

Poch T, et al. (2024) Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis. Cell reports. Medicine, 5(7), 101620.

Hammer Q, et al. (2024) Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. Cell stem cell, 31(9), 1376.

Akahata W, et al. (2023) Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study. Cell reports. Medicine, 4(8), 101134.

Ahmed A, et al. (2023) BCG revaccination in adults enhances pro-inflammatory markers of trained immunity along with anti-inflammatory pathways. iScience, 26(10), 107889.

Saggau C, et al. (2022) The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination. Immunity, 55(10), 1924.

Xue J, et al. (2022) Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. Cell, 185(1), 131.

Nogimori T, et al. (2022) Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination. Frontiers in immunology, 13, 1081047.

Vierboom MPM, et al. (2021) Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination. Cell reports. Medicine, 2(1), 100185.

Dijkman K, et al. (2021) Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection. Cell reports. Medicine, 2(1), 100187.

Bacher P, et al. (2020) Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. Immunity, 53(6), 1258.

Körner C, et al. (2017) HIV-1-Mediated Downmodulation of HLA-C Impacts Target Cell Recognition and Antiviral Activity of NK Cells. Cell host & microbe, 22(1), 111.